Sleep Quality, Cognitive Performance, and Computerized Cognitive Training
Withdrawn · NCT06328140
Conditions: Bipolar Disorder, Major Depressive Disorder, Psychosis
At a glance
- Research payments reported, 2025
- $59,719
- U.S. investigators named
- 1
- Sites paid
- 1
About the trial
- Sponsor
- George West Mental Health Foundation d/b/a Skyland Trail (with Sumitomo Pharmaceuticals America)
- Tested
- Lurasidone (drug), FDA Approved antidepressant treatment (drug)
- Dates
- Started 2024-04-15; completion 2025-01-22
- Results posted
- Not yet
Poor sleep quality is common in neuropsychiatric conditions and some of the problems associated with poor sleep at night may be due to medication side effects or reduced efficacy of certain treatments. Poor sleep quality has been implicated in cognitive impairments, with the sleep quality to cognition association so strong that specialized assessments have been developed to examine the subjective association between poor nighttime sleep and daytime cognitive impairment. Computerized cognitive training (CCT) is a training procedure designed to build cognitive skills, with a goal of improvement of functional outcomes. CCT is also a learning-based approach and previous studies have shown tha…
From ClinicalTrials.gov, last updated 2025-05-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma Co., Ltd. reported $59,719 in research payments for this study in 2025 (1 payments).
Products named: Latuda
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- George West Mental Health Foundation Inc DBA Skyland Trail $59,719
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.